Nuvectis Pharma Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr '26 Apr 28, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Market Cap	230	194	105	145	114	-
Market Cap Growth	15.45%	83.80%	-27.40%	27.51%	-	-
Enterprise Value	198.58	162.23	86.94	126.15	93.94	0
Last Close Price	8.69	7.55	5.41	8.34	7.50	-
PE Ratio	-	-5.72	-4.87	-5.83	-4.97	-
PB Ratio	12.12	10.53	10.86	11.91	8.01	-
P/TBV Ratio	10.29	8.94	9.53	10.63	6.68	-
P/FCF Ratio	-	-12.11	-8.61	-9.11	-8.40	-
P/OCF Ratio	-	-12.11	-8.61	-9.11	-8.40	-
EV/EBITDA Ratio	-	-5.88	-4.38	-5.51	-4.88	-
EV/EBIT Ratio	-	-5.88	-4.38	-5.51	-4.88	-
EV/FCF Ratio	-	-10.13	-7.10	-7.91	-6.93	-
Net Debt / Equity Ratio	-1.72	-1.72	-1.91	-1.57	-1.41	0.52
Net Debt / EBITDA Ratio	1.15	1.15	0.93	0.84	1.04	0.45
Net Debt / FCF Ratio	1.98	1.98	1.51	1.20	1.48	0.60
Quick Ratio	2.38	2.38	2.08	2.74	3.23	2.37
Current Ratio	2.38	2.38	2.09	2.75	3.30	2.41
Return on Equity (ROE)	-188.03%	-188.03%	-173.41%	-168.51%	-206.81%	-609.75%
Return on Assets (ROA)	-109.60%	-109.60%	-105.03%	-115.67%	-142.15%	-387.38%
Return on Invested Capital (ROIC)	250.21%	250.21%	252.10%	373.86%	640.71%	3737.39%
Return on Capital Employed (ROCE)	-196.07%	-196.07%	-181.13%	-173.33%	-208.42%	-609.93%
Earnings Yield	-12.54%	-17.48%	-20.52%	-17.15%	-20.13%	-
FCF Yield	-	-8.26%	-11.61%	-10.98%	-11.90%	-
Buyback Yield / Dilution	-27.46%	-27.46%	-10.01%	-22.90%	-196.55%	-9.44%
Total Shareholder Return	-27.46%	-27.46%	-10.01%	-22.90%	-196.55%	-9.44%

Updated Feb 11, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q